Merck KGaA Previews Cladribine Regulatory Revival Story At ECTRIMS

With the EMA’s review of the latest MAA for cladribine ongoing, Merck KGaA uses ECTRIMS 2016 to showcase longer-term efficacy data and a safety analysis that could lay to rest concerns about the multiple sclerosis therapy's risk of malignancy.

Merck KGAA gave a look at the new data and analyses behind its renewed push for approval of the multiple sclerosis candidate cladribine at the recent 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2016).

The purine nucleotide analog was the subject of an ample number of presentations at the conference in London, including analyses...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from R&D

More from Pink Sheet